These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35027383)

  • 1. Akatsuki disease in a patient using an epidermal growth factor receptor-tyrosine kinase inhibitor.
    Oda N; Nakagawa Y; Takata I
    BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35027383
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.
    Hong S; Gao F; Fu S; Wang Y; Fang W; Huang Y; Zhang L
    JAMA Oncol; 2018 May; 4(5):739-742. PubMed ID: 29596544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
    Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
    Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
    Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
    Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
    Azuma K; Nishio M; Hayashi H; Kiura K; Satouchi M; Sugawara S; Hida T; Iwamoto Y; Inoue A; Takeda K; Ikeda S; Nakagawa T; Takeda K; Asahina S; Komatsu K; Morita S; Fukuoka M; Nakagawa K
    Cancer Sci; 2018 Aug; 109(8):2532-2538. PubMed ID: 29807396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
    Tartarone A; Lerose R; Lazzari C; Gregorc V; Aieta M
    Med Oncol; 2014 Aug; 31(8):78. PubMed ID: 24958518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib in non small cell lung cancer.
    Costanzo R; Piccirillo MC; Sandomenico C; Carillio G; Montanino A; Daniele G; Giordano P; Bryce J; De Feo G; Di Maio M; Rocco G; Normanno N; Perrone F; Morabito A
    J Biomed Biotechnol; 2011; 2011():815269. PubMed ID: 21660144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
    Ohashi K; Maruvka YE; Michor F; Pao W
    J Clin Oncol; 2013 Mar; 31(8):1070-80. PubMed ID: 23401451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical mutation of epidermal growth factor receptor in resected stage I non-small-cell lung cancers.
    Etienne H; Goudou T; Assouad J
    Eur J Cardiothorac Surg; 2024 Jan; 65(1):. PubMed ID: 38145494
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].
    Zhou M; Chen DM; Xia L; Song YY; Shi YK; Yang ZM
    Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):949-952. PubMed ID: 31874554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review.
    Imakita T; Matsumoto H; Hirano K; Morisawa T; Sakurai A; Kataoka Y
    BMC Cancer; 2019 Jan; 19(1):105. PubMed ID: 30683066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
    Miyamoto S; Azuma K; Ishii H; Bessho A; Hosokawa S; Fukamatsu N; Kunitoh H; Ishii M; Tanaka H; Aono H; Nakahara Y; Kusaka K; Hosomi Y; Kikuchi N; Mori Y; Itani H; Hamada A; Yamada K; Okamoto H
    JAMA Oncol; 2020 Jul; 6(7):e201250. PubMed ID: 32407455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
    Jänne PA; Yang JC; Kim DW; Planchard D; Ohe Y; Ramalingam SS; Ahn MJ; Kim SW; Su WC; Horn L; Haggstrom D; Felip E; Kim JH; Frewer P; Cantarini M; Brown KH; Dickinson PA; Ghiorghiu S; Ranson M
    N Engl J Med; 2015 Apr; 372(18):1689-99. PubMed ID: 25923549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
    Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
    Saijo N
    Nat Rev Clin Oncol; 2010 Nov; 7(11):618-9. PubMed ID: 20981125
    [No Abstract]   [Full Text] [Related]  

  • 19. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.
    Pao W; Chmielecki J
    Nat Rev Cancer; 2010 Nov; 10(11):760-74. PubMed ID: 20966921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.
    Oxnard GR; Arcila ME; Chmielecki J; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2011 Sep; 17(17):5530-7. PubMed ID: 21775534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.